Pyoderma gangrenosumhttps://en.wikipedia.org/wiki/Pyoderma_gangrenosum
Pyoderma gangrenosum ass eng selten, entzündlech Hautkrankheet, wou schmerzhafte Pustelen oder Knollen Geschwüren ginn, déi progressiv wuessen. Pyoderma gangrenosum ass net infektiiv. Behandlungen kënnen Corticosteroiden, Ciclosporin oder verschidde monoklonal Antikörper enthalen. Och wann et Leit vun all Alter beaflosse kann, betrëfft et meeschtens Leit an hire 40er a 50er.

☆ An den 2022 Stiftung Warentest Resultater aus Däitschland war d'Zefriddenheet vum Konsument mam ModelDerm nëmme liicht manner wéi mat bezuelte Telemedizin Konsultatiounen.
  • Um Been vun enger Persoun mat colitis ulcerative.
References Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments 35606650 
NIH
Pyoderma gangrenosum ass e rare Hautbedingung, dee schmerzhafte Geschwüre mat roude oder purpurroude Kanten verursaacht. Et ass als entzündlech Krankheet klasséiert an ass Deel vun enger Grupp genannt neutrophil Dermatosen. D'Ursaach vum pyoderma gangrenosum ass komplex, involvéiert Probleemer mat souwuel gebuerene wéi adaptiven Immunitéit bei Leit déi genetesch ufälleg sinn. Viru kuerzem hunn d'Fuerscher sech op d'Hoerfollikel als potenziellen Ausgangspunkt vun der Krankheet konzentréiert.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
 Pyoderma Gangrenosum: Treatment Options 37610614 
NIH
Pyoderma gangrenosum ass e rare Hautzoustand deen extrem schmerzhafte Geschwëster verursaacht. Och wa mir seng Ursaach net ganz verstinn, wësse mir datt et eng erhéicht Aktivitéit vu bestëmmten Immunzellen involvéiert. D'Behandlung vun der Krankheet ass nach ëmmer net einfach. Mir hunn verschidden Medikamenter déi den Immunsystem ënnerdrécken oder seng Aktivitéit änneren. Nieft dësen konzentréiere mir eis och op d'Behandlung vun de Wounds an d'Behandlung vu Péng. Corticosteroiden a Cyclosporin sinn dacks déi éischt Wiel fir d'Behandlung, awer zënter kuerzem gouf et méi Fuerschung iwwer d'Benotzung vu biologesche Therapien wéi TNF-α Inhibitoren. Dës Biologie ginn ëmmer méi bevorzugt, besonnesch bei Patienten mat aneren entzündleche Konditiounen, a si gi méi fréi am Krankheetsprozess benotzt.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.